Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment
2023年11月2日 - 6:50AM
Dow Jones News
By Sabela Ojea
Phathom Pharmaceuticals said the U.S. Food and Drug
Administration approved Voquezna to treat a type of esophagus
inflammation.
The commercial-stage biopharmaceutical company said the FDA
approved the novel potassium-competitive acid blocker as a new
treatment for adults dealing with erosive esophagitis.
The approval is based on positive results from the phase 3
Phalcon-EE study, which enrolled over 1,000 patients in the U.S.
and Europe.
Voqezna is expected to be available in the U.S. in December, the
company said.
The FDA approval entitles Phathom Pharmaceuticals to receive a
$175 million payment, which will fund the commercial launch.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 01, 2023 17:35 ET (21:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Phathom Pharmaceuticals (NASDAQ:PHAT)
過去 株価チャート
から 4 2024 まで 5 2024
Phathom Pharmaceuticals (NASDAQ:PHAT)
過去 株価チャート
から 5 2023 まで 5 2024
